Dyne Therapeutics Inc.

Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervous system. Dyne's lead programs address significant unmet medical needs in conditions including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company is advancing multiple candidates through clinical development, with key programs progressing toward regulatory milestones and potential commercialization. Dyne operates in the rare disease biotechnology space, serving patients with limited treatment options and positioning itself for potential market entry as its pipeline candidates mature toward approval and launch.